User:Matthew Pereira/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
==Introduction== | ==Introduction== | ||
[https://en.wikipedia.org/wiki/COVID-19 COVID-19] | [https://en.wikipedia.org/wiki/COVID-19 COVID-19] | ||
| + | The viral SARS-CoV-2 membrane is covered in [https://en.wikipedia.org/wiki/Coronavirus_spike_protein spike proteins]. These proteins are what enable the virus to enter our cells via interaction with membrane surface proteins called "angiotensin-converting enzyme 2" (ACE-2) receptors. SARS-CoV-2 spike proteins <scene name='10/1075220/Spikeboundtoace-2/1'>bind with these receptors</scene> to induce phagocytosis of the receptor-viral body complex. | ||
==Function== | ==Function== | ||
The minibinder associates with the SARS-CoV-2 spike protein binding domain for ACE-2 before it reaches a host cell. <scene name='10/1075220/Spikeblockedbyminibinder/1'>This prevents association with ACE-2.</scene> | The minibinder associates with the SARS-CoV-2 spike protein binding domain for ACE-2 before it reaches a host cell. <scene name='10/1075220/Spikeblockedbyminibinder/1'>This prevents association with ACE-2.</scene> | ||
Revision as of 19:40, 1 April 2025
SARS-CoV-2 De Novo Designed Minibinders
| |||||||||||
References
- ↑ Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020 Oct 23;370(6515):426-431. PMID:32907861 doi:10.1126/science.abd9909
Student Contributors
Matt Pereira, Giavanna Yowel, and Shae Bailey
